Sandra Ciesek, Eike Steinmann, Heiner Wedemeyer, Michael P. Manns, Johann Neyts, Norbert Tautz, Vanesa Madan, Ralf Bartenschlager, Thomas von Hahn, Thomas Pietschmann – 29 October 2009 – Numerous anti‐hepatitis C virus (HCV) drugs targeting either the viral nonstructural 3 (NS3) protease or NS5B polymerase are currently in clinical testing. However, rapid resistance development is a major problem and optimal therapy will clearly require a combination of multiple mechanisms of action.

Jean‐Charles Duclos‐Vallee, Mylène Sebagh – 29 October 2009 – Key Points

Hillary Bownik, Sammy Saab – 29 October 2009 – Key Points

Olaf Guckelberger – 29 October 2009 – Key Points

J. Ignacio Herrero – 29 October 2009 – Key Points

Nora Frulio, Hervé Laumonier, Charles Balabaud, Hervé Trillaud, Paulette Bioulac‐Sage – 29 October 2009

Michael Charlton – 29 October 2009 – Key Points

Stefan Hübscher – 29 October 2009 – Key Points

Jeffrey J. Germer, Carl E. Bommersbach, Dana M. Schmidt, Jordan L. Bendel, Joseph D. C. Yao – 29 October 2009

Pierre Nahon, Angela Sutton, Pierre Rufat, Marianne Ziol, Hassan Akouche, Christelle Laguillier, Nathalie Charnaux, Nathalie Ganne‐Carrié, Véronique Grando‐Lemaire, Gisèle N'Kontchou, Jean‐Claude Trinchet, Liliane Gattegno, Dominique Pessayre, Michel Beaugrand – 29 October 2009 – Alcohol increases reactive oxygen species (ROS) formation in hepatocyte mitochondria and by reduced nicotinamide adenine dinucleotide phosphate oxidases and myeloperoxidase (MPO) in Kupffer cells and liver‐infiltrating neutrophils.